AVEO's Ficlatuzumab in Combination with Gefinitib Well Tolerated in Patients with Non-Small Cell Lung Cancer; Phase 1b Data Presented at ASCO - MarketWatch - http://www.marketwatch.com/story...
RT @Rndubois: AVEO's Ficlatuzumab Well Tolerated in Patients with Non-Small Cell Lung Cancer: http://tinyurl.com/4x6u5o9 - Sally Church